Table 2.

FLT3 kinase domain mutations observed in patients during sequential therapy with sorafenib and sunitinib by next generation sequencing.

Patient Number	Sample	Blasts (%)	Mutation frequency (%)a			Coverage D835H/Y/F691L (number of reads x 1000)
			D835H	D835Y	F691L
1	Pre-treatment	80	ND	ND	ND	109/103
	During sorafenib (day 11)	38	ND	ND	ND	163/94
	During sorafenib (day 91)	39	ND	ND	ND	138/83
	Sorafenib resistance (day 176)	93	33.1	ND	ND	30/44
	During sunitinib (day 29)	35	14.4	ND	ND	5.4/61
2	Pre-treatment	77	ND	ND	ND	122/82
	Sorafenib resistance (day 389)	57	35.7	0.63	0.16	29/79
	During sunitinib (day 36)	53	28.2	1.03	ND	46/142
3	Pre-treatment	48	ND	ND	ND	123/57
	During sorafenib (day 53)	2.1b	0.023	ND	ND	110/73
	During sorafenib (day 97)	2.1b	0.029	ND	0.075	86/82
	Sorafenib resistance (day 158)	59	11.0	4.0	18.2	27/55
	During sunitinib (day 57)	92	19.2	16.2	3.9	76/132
	Sunitinib resistance (day 99)	70	13.5	28.5	2.9	28/87
4	Pre-treatment	62	ND	ND	ND	96/66
	During sorafenib (day 50)	25	ND	ND	ND	95/80
5	Pre-treatment	34	ND	ND	ND	85/83
	During sorafenib (day 36)	27	ND	0.10	ND	107/75
6	Pre-treatment	75	ND	ND	ND	35/160
	During sorafenib (day 36)	25	ND	ND	ND	146/188

^aAbbreviations: ND, not detected.

^bMinimal residual disease sample.